Cost Benefit Study Supports the Use of Longport's Technology in Pressure Ulcer Prevention

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency high resolution ultrasound imaging, today announced 
      interim results from a cost benefit study supporting the use of its 
      EPISCAN I-200 system as an evidence based pressure ulcer prevention 
      tool. Study results showed an expected cost-savings per at-risk resident 
      of $5,341.00 per year with use of the EPISCAN in concert with current 
      practice standards for pressure ulcer prevention when compared to 
      current pressure ulcer prevention measures alone. Statistical Analysis 
      using Monte Carlo simulation showed the use of the EPISCAN Ultrasound 
      diagnosis to be the preferred option 73.7% of the time and that the 
      decision to use the EPISCAN was very robust and changed only when the 
      incidence of pressure ulceration was below 3.0% in the standard 
      evidence-based group.
    
    
      The study, which is still on-going, is being undertaken at an extended 
      care rehabilitation nursing home in upstate New York. These interim 
      findings are being presented by Ron Shannon, the principal investigator 
      at the Symposium on Advanced Wound Care (SAWC) and The Wound Healing 
      Society (WHS) meeting in Tampa, Florida (April 28 – 
      May 1, 2007).
    
    
      Mr. Shannon said, “The timing is right for a 
      cost-effective, diagnostic tool that will give early insight into 
      non-visible pressure ulcer injury so treatment and prevention can begin 
      early. The morbidity associated with the development of pressure ulcers 
      increases patient suffering, nurses’ workload 
      and risk of death. Pressure ulcers also increase the length of stay and 
      resultant expense of hospitalization, hardly affordable consequences in 
      today’s era of health care economics. We 
      conclude that the EPISCAN, in extended care rehabilitation units, is a 
      cost-benefit to providers for preventing costly pressure ulcers.”
    
    
      Connie Phillips-Jones, RN, MSN, Director of Clinical Support, said, “This 
      is an exciting conclusion and supports the use of the EPISCAN I-200 and 
      will contribute to clinical acceptance based on evidence.”
    
    
      Further details on this presentation and other clinical study papers can 
      be viewed at the News section of Longport’s 
      WEB site.
    
    
      http://www.longportinc.com/about/news.html
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high resolution ultrasound imaging. After 
      several years and a multi-million dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.